These results suggest that Swertianin may activate PPARG expression, effectively improving hepatic lipid deposition and inflammatory conditions in the MASLD mouse model and thereby alleviating liver damage. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.